Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Ancillary testing in lung cancer diagnosis.

Dubinski W, Leighl NB, Tsao MS, Hwang DM.

Pulm Med. 2012;2012:249082. doi: 10.1155/2012/249082. Epub 2012 Jan 4.

2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
3.

Tumors in the lung--morphologic features and the challenge of integrating biomarker signatures into diagnostics.

Vollmer E, Schultz H, Stellmacher F, Kähler D, Abdullah M, Galle J, Lang DS, Goldmann T.

Rom J Morphol Embryol. 2010;51(4):607-14. Review.

4.

Role of ancillary studies in fine-needle aspiration from selected tumors.

Schmitt F, Barroca H.

Cancer Cytopathol. 2012 Jun 25;120(3):145-60. doi: 10.1002/cncy.20197. Epub 2011 Nov 1. Review.

5.

Revolution in lung cancer: new challenges for the surgical pathologist.

Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM.

Arch Pathol Lab Med. 2011 Jan;135(1):110-6. doi: 10.1043/2010-0567-RA.1. Review.

PMID:
21204716
6.

EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens.

Wei EX, Anga AA, Martin SS, Jackson JG, Nordberg ML, Herrera GA, Turbat-Herrera EA.

Mod Pathol. 2007 Sep;20(9):905-13. Epub 2007 Jul 20.

7.

Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis.

Maldonado F, Jett JR.

Curr Opin Pulm Med. 2010 Jul;16(4):315-20. doi: 10.1097/MCP.0b013e328337f938. Review.

PMID:
20173641
8.
9.

Cancer Drug Development: New Targets for Cancer Treatment.

Curt GA.

Oncologist. 1996;1(3):II-III.

PMID:
10387987
10.

The prognostic application of cytokeratin typing of nonsmall cell lung carcinoma. A retrospective study.

Cohen R, Guber A, Siegal A, Bruderman I, Huszar M, Yellin A, Marom Z, Geiger B.

Cancer. 1997 Feb 1;79(3):468-73.

PMID:
9028356
11.

Predictive pathology in routine diagnostics of solid tumors.

Lassmann S, Werner M.

Histol Histopathol. 2012 Mar;27(3):289-96. Review.

PMID:
22237706
12.

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS.

J Urol. 2005 Jun;173(6):1853-62. Review.

PMID:
15879764
13.

The classification of lung carcinoma: time to change the morphology-based approach?

Pelosi G, Sonzogni A, Viale G.

Int J Surg Pathol. 2010 Jun;18(3):161-72. doi: 10.1177/1066896910361736.

PMID:
20460313
14.
15.

Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.

Facey K, Bradbury I, Laking G, Payne E.

Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267. Review.

16.

A critical appraisal of prognostic and predictive factors for common lung cancers.

Thunnissen FB, Schuurbiers OC, den Bakker MA.

Histopathology. 2006 Jun;48(7):779-86. Review.

PMID:
16722925
17.

A technique to improve diagnostic information from fine-needle aspirations: immunohistochemistry on cytoscrape.

Skov BG, Kiss K, Ramsted J, Linnemann D.

Cancer. 2009 Apr 25;117(2):120-7. doi: 10.1002/cncy.20005.

18.

An analysis of the impact of pathology review in gynecologic cancer.

Chafe S, Honore L, Pearcey R, Capstick V.

Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1433-8.

PMID:
11121644
19.
20.

Variability in interpretation of immunohistologic findings in lymphoproliferative disorders by hematopathologists. A comprehensive statistical analysis of interobserver performance.

Sheibani K, Nathwani BN, Swartz WG, Ben-Ezra J, Brownell MD, Burke JS, Kennedy JL, Koo CH, Winberg CD.

Cancer. 1988 Aug 15;62(4):657-64.

Items per page

Supplemental Content

Write to the Help Desk